Charles River Laboratories International, Inc. (CRL): Price and Financial Metrics
Charles River Laboratories International, Inc. (CRL)
Today's Latest Price: $280.18 USD
Updated Jan 22 7:00pm
Add CRL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
CRL Stock Summary
- CRL has a higher market value than 85.6% of US stocks; more precisely, its current market capitalization is $13,989,616,136.
- With a one year PEG ratio of 177.64, Charles River Laboratories International Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 81.81% of US stocks.
- The price/operating cash flow metric for Charles River Laboratories International Inc is higher than 77.9% of stocks in our set with a positive cash flow.
- Stocks that are quantitatively similar to CRL, based on their financial statements, market capitalization, and price volatility, are PRAH, BR, TTEK, RXN, and FOXA.
- Visit CRL's SEC page to see the company's official filings. To visit the company's web site, go to www.criver.com.
CRL Stock Price Chart Interactive Chart >
CRL Price/Volume Stats
Current price | $280.18 | 52-week high | $284.60 |
Prev. close | $281.24 | 52-week low | $95.58 |
Day low | $277.36 | Volume | 169,500 |
Day high | $282.09 | Avg. volume | 325,221 |
50-day MA | $247.80 | Dividend yield | N/A |
200-day MA | $208.60 | Market Cap | 13.94B |
Charles River Laboratories International, Inc. (CRL) Company Bio
Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.
CRL Price Forecast Based on DCF Valuation
Current Price | DCF Fair Value Target: | Forecasted Gain: |
$280.18 | $154.79 | -45% |
We started the process of determining a valid price forecast for Charles River Laboratories International Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Charles River Laboratories International Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Charles River Laboratories International Inc, consider:
- 87% of the company's capital comes from equity, which is greater than 66.47% of stocks in our cash flow based forecasting set.
- The weighted average cost of capital for the company is 9. This value is greater than just 23.35% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
0% | -46% |
1% | -45% |
2% | -45% |
3% | -44% |
4% | -44% |
5% | -43% |
Want more companies with a valuation profile/forecast similar to that of Charles River Laboratories International Inc? See MMSI, MGLN, PKI, ITGR, and IART.
Loading social stream, please wait...